Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Population trends in use of oral antidiabetic drugs

From: Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies

  2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Overall           
 Patient Number 527,045 579,017 624,540 689,423 736,743 784,132 843,334 903,947 969,161 1,025,646
 Volume/patient (DDDs)c. 585.94 613.85 640.25 650.54 652.36 651.68 653.71 637.1 630.16 635.59
 Expenditure/patient (US$)d. 162.80 199.99 219.48 241.64 233.55 232.84 216.31 207.33 205.63 195.34
Subgroups by class           
Volume/patient (DDDs) c.           
 Biguanides 125.11 127.77 129.51 133.68 137.99 141.71 144.18 144.81 143.07 138.19
 Sulfonylureas 449.33 453.46 458.54 444.33 421.16 410.44 399.74 379.16 354.72 325.44
 Alpha-glucosidase inhibitors 3.64 5.97 10.72 13.81 14.67 16.13 18.04 19.35 19.34 19.21
 Thiazolidinediones 3.23 16.04 27.48 34.15 31.15 32.64 36.64 37.44 36.66 38.4
 Dipeptidyl peptidase-4 inhibitors N/A b. N/A N/A N/A N/A N/A N/A N/A 10.17 27.40
 Othersa. 4.63 10.61 14.00 24.56 47.38 51.12 55.12 56.35 66.21 85.93
Expenditure/patient (US$) d.           
 Biguanides 51.20 51.67 46.46 46.73 46.99 44.42 34.65 32.88 32.47 28.97
 Sulfonylureas 94.38 98.10 95.10 98.36 96.40 94.07 85.00 81.35 74.84 59.13
 Alpha-glucosidase inhibitors 4.94 7.41 12.46 15.81 16.52 17.87 18.54 18.45 17.39 15.06
 Thiazolidinediones 7.70 33.85 53.87 66.64 60.65 62.64 64.40 60.83 55.67 48.42
 Dipeptidyl peptidase-4 inhibitors N/A N/A N/A N/A N/A N/A N/A N/A 11.68 31.13
 Othersa. 4.59 8.97 11.59 14.10 12.99 13.84 13.72 13.80 13.58 12.63
  1. a. Others: guar gum, repaglinide, nateglinide, exenatide, liraglutide, mitiglinide.
  2. b. N/A = not applicable.
  3. c. Volume/patients (DDDs) = aggregated annual volume (DDDs) of prescription/annual number of diabetic patient.
  4. d. Expenditure/patient (US$) = aggregated annual expenditure (US$) of prescription/annual number of diabetic patient.